Ouyang Jiang, Liu Ren-Yu, Chen Wansong, Liu Zhenjun, Xu Qunfang, Zeng Ke, Deng Liu, Shen Liangfang, Liu You-Nian
College of Chemistry and Chemical Engineering, Central South University, Changsha, Hunan 410083, China.
J Mater Chem B. 2018 Oct 21;6(39):6302-6310. doi: 10.1039/c8tb01669k. Epub 2018 Sep 13.
In the fight against pathogenic bacteria, traditional antibiotic therapy is challenged by low efficiency and drug resistance. These drawbacks motivate the development of synergistic antibacterial therapy, but there is a lack of efficient synergistic platforms. Herein, with methicillin-resistant Staphylococcus aureus (MRSA) as a pathogenic bacterial model, we explored the potential of black phosphorus (BP) as a synergistic therapeutic platform for drug resistant bacterial infection. Acting as a substrate, reductant and stabilizer, BP nanosheets were decorated with Ag nanoparticles (NP) through an in situ growth strategy. The photothermal effect of the BP nanosheets allows Ag@BP nanohybrids to rapidly disrupt a bacterial membrane under near infrared (NIR) light irradiation. Moreover, the slowly released Ag elevates oxidative stress and sustainably suppresses bacterial proliferation for a long time. The combination of these two aspects endows the Ag@BP nanohybrids with synergistically enhanced antibacterial performance. Different from traditional antibiotics, the antibacterial effects of the Ag@BP nanohybrids are independent of the bacterial structure, which bypasses the issue of drug resistance. The in vivo studies show that the Ag@BP nanohybrids efficiently decrease the MRSA bacterial burden in mice and minimize infection associated tissue lesions. Besides, the excellent biocompatibility of the Ag@BP nanohybrids guarantees their biosafety for future clinical applications. Accordingly, this work demonstrates the potential of the BP nanosheets in the synergistic antibacterial therapy against drug resistant bacteria, and paves the way for developing 2D semiconductor based synergistic antibacterial nanodrugs.
在对抗病原菌的过程中，传统抗生素疗法面临着效率低下和耐药性的挑战。这些缺点促使人们开发协同抗菌疗法，但目前缺乏高效的协同平台。在此，我们以耐甲氧西林金黄色葡萄球菌（MRSA）作为病原菌模型，探索了黑磷（BP）作为耐药细菌感染协同治疗平台的潜力。通过原位生长策略，BP纳米片作为底物、还原剂和稳定剂，负载了银纳米颗粒（NP）。BP纳米片的光热效应使Ag@BP纳米杂化物在近红外（NIR）光照射下能迅速破坏细菌膜。此外，缓慢释放的银会加剧氧化应激，并长期持续抑制细菌增殖。这两个方面的结合赋予了Ag@BP纳米杂化物协同增强的抗菌性能。与传统抗生素不同，Ag@BP纳米杂化物的抗菌效果与细菌结构无关，从而绕过了耐药性问题。体内研究表明，Ag@BP纳米杂化物能有效降低小鼠体内的MRSA细菌载量，并将感染相关的组织损伤降至最低。此外，Ag@BP纳米杂化物优异的生物相容性保证了其在未来临床应用中的生物安全性。因此，这项工作证明了BP纳米片在协同抗耐药菌治疗中的潜力，并为开发基于二维半导体的协同抗菌纳米药物铺平了道路。
